Aerosol devices and asthma therapy

Current Drug Delivery

Volumn 6, Issue 1, 2009, Pages 38-49

  Berger, William ^a  

^a Allergy and Asthma Associates of Southern CA   (United States)

Author keywords

Aerosol devices; Asthma therapy; HFA; MDI; Nebulizers; pMDI

Indexed keywords

ACCUNEB; ASMABEC; ASMASAL; ATIMOS; BECLOMETASONE; BECLOMETASONE DIPROPIONATE; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CHLOROFLUOROCARBON; CICLESONIDE; CORTICOSTEROID; FLUNISOLIDE; FLUORINATED HYDROCARBON; FLUTICASONE; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; FORMOTEROL FUMARATE; LEVALBUTEROL; MOMETASONE FUROATE; ORCIPRENALINE; PIRBUTEROL; PIRBUTEROL ACETATE; PROCATEROL; PROPELLANT; SALBUTAMOL; SALBUTAMOL SULFATE; SALMETEROL; SALMETEROL XINAFOATE; TERBUTALINE; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

AEROSOL; ASTHMA; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; HUMAN; LUNG DEPOSIT; METERED DOSE INHALER; NEBULIZER; POWDER INHALER; PRIORITY JOURNAL; REVIEW;

AEROSOLS; ASTHMA; HUMANS; LUNG; METERED DOSE INHALERS; NEBULIZERS AND VAPORIZERS; POWDERS;

EID: 61849131253     PISSN: 15672018     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720109787048203     Document Type: Review

References (80)

1. Hess, D.R. Metered-dose inhalers and dry powder inhalers in aerosol therapy. Respir. Care, 2005, 50, 1376-83.
2. Tiddens, H. Matching the device to the patient. Pediatr. Pulmonol., 2004, S26, 26-9.
3. Dalby, R.; Suman, J. Inhalation therapy: technological milestones in asthma treatment. Adv. Drug Deliv. Rev., 2003, 55, 779-81.
4. Anderson, P.J. History of aerosol therapy: liquid nebulization to MDIs to DPIs. Respir. Care, 2005, 50, 1139-49.
5. Grossman, J. The evolution of inhaler technology. J. Asthma, 1994, 31, 55-64.
6. Rubin, B.K.; Fink, J.B. Optimizing aerosol delivery by pressurized metered-dose inhalers. Respir. Care, 2005, 50, 1191-7.
7. The Montreal Protocol on Substances That Deplete the Ozone Layer; final act (UNEP: Nairobi, 1984). Federal Register 59FR 56276-98, 1994.
8. Leach, C.L. The CFC to HFA transition and its impact on pulmonary drug development. Respir. Care, 2005, 50, 1201-6.
9. DeBenedictis, F.M.; Selvaggio, D. Use of inhaler devices in pediatric asthma. Pediatr. Drugs, 2003, 5, 629-38.
10. Geller, D.E. Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler. Respir. Care, 2005, 50, 1313-21.
11. Berger, W.E. Paediatric pulmonary drug delivery: considerations in asthma treatment. Expert Opin. Drug Deliv., 2005, 2, 965-80.
12. Global Initiative for Asthma (GINA). Guidelines and resources http://.http://www.ginasthma.com/GuidelinesResources.asp? 11=2&l2=0 (accessed June 9, 2008).
13. Telko, M.J.; Hickey, A.J. Dry powder inhaler formulation. Respir. Care, 2005, 50, 1209-27.
14. Newman, S.P. Principles of metered-dose inhaler design. Respir. Care, 2005, 50, 1177-88.
15. Dolovich, M.B.; Ahrens, R.C.; Hess, D.R.; Anderson, P.; Dhand, R.; Rau, J.L; Smaldone, G.C.; Guyatt, G. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest, 2005, 127, 335-71.
16. National Heart, Lung, and Blood Institute. Expert Panel Report 3 (EPR3): Guidelines for the diagnosis and management of asthma. http://www.nhlbi.nih.gov/ guidelines/asthma/asthgdln.htm (accessed June 9, 2008).
17. Nikander, K.; Turpeinen, M.; Wollmer, P. The conventional ultrasonic nebulizer proved inefficient in nebulizing a suspension. J. Aerosol. Med., 1999, 12, 47-53.
18. Dolovich, M.A.; MacIntyre, N.R.; Anderson, P.J.; Camargo Jr., C.A.; Chew, N.; Cole; C.H.; Dhand, R.; Fink, J.B.; Gross; N.J.; Hess D.R.; Hickey, A.J.; Kim, C.S.; Martonen, T.B.; Pierson, D.J.; Rubin; B.K.; Smaldone, G.C. Consensus statement: aerosols and delivery devices. American Association for Respiratory Care. Respir. Care, 2000, 45, 589-96.
19. Chapman, K.R.; Love, L.; Brubaker, H. A comparison of breath-actuated and conventional metered-dose inhaler inhalation techniques in elderly subjects. Chest, 1993, 104, 1332-7.
20. Keller, M. Innovations and perspectives of metered dose inhalers in pulmonary drug delivery. Int. J. Pharm., 1999, 186, 81-90.
21. U.S. Food and Drug Administration. Guidance for industry: integration of dose-counting mechanisms into MDI drug products. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). http://www.fda.gov/cder/guidance/5308FNL.htm (accessed December 17, 2006).
22. Smaldone, G.C.; Cruz-Rivera, M.; Nikander, K. In vitro determination of inhaled mass and particle distribution for budesonide nebulizing solution. J. Aerosol. Med., 1998, 11, 113-25.
23. American Academy of Allergy Asthma & Immunology. Drug guide. http://www.aaaai.org/patients/resources/medication-guide/ (accessed June 14, 2007).
24. Brocklebank, D.; Ram, F.; Wright, J.; Barry, P.; Cates, C.; Davies, L.; Douglas, G.; Muers, M.; Smith, D.; White, J. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol. Assess., 2001, 5, 1-155.
25. Polli, G.P.; Grim, W.M.; Bacher F.A.; Yunker, M.H. Influence of formulation on aerosol particle size. J. Pharm. Sci., 1969, 58, 484-6.
26. Clark, A.R. MDIs: physics of aerosol formation. J. Aerosol. Med., 1996, 9, S19-26.
27. Noakes, T. Medical aerosol propellants. J. Fluor. Chem., 2002, 118, 35-45.
28. Use of Ozone-Depleting Substances; Removal of Essential-Use Designations, Final Rule. Federal Register 17168 (codified at 21 CFR Part 2), 2005.
29. Leach, C.L; Davidson, P.J.; Boudreau, R.J. Improved airway targeting with the CFC-free HFA-beclomethasone metered dose inhaler compared with CFC-beclomethasone. Eur. Res. J., 1998, 12, 1346-53.
30. Leach, C.L; Davidson, P.J.; Hasslequist, B.E; Boudreau, R.J. Lung deposition of HFA-beclomethasone is greater than that of CFC-fluticasone and CFC-beclomethasone: a cross-over study in healthy volunteers. Chest, 2002, 122, 510-6.
31. Busse, W.W.; Branzinsky, S.; Jacobson, K.; Stricker, W.; Schmitt, K.; Vanden Burgt, J; Donnell, D.; Hannon, S.; Colice, G.L. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J. Allergy Clin. Immunol., 1999, 104, 1215-22.
32. Harrison, L.I. Local versus total systemic bioavailability of beclomethasone dipropionate CFC and HFA metered dose inhaler formulations. J. Aerosol. Med., 2002, 15, 401-6.
33. Boulet, L.P.; Cartier, A.; Ernst, P.; Larivee, P. Laviolette, M. Safety and efficacy of HFA-134a beclomethasone dipropionate extra-fine aerosol over six months. Can. Respir. J., 2004, 11, 123-30.
34. Vastagh, E.; Kuna, P.; Calistruc, P.; Bogdan, M.A.; Budesonide HFA MDI Study Group. Efficacy and safety of inhaled budesonide delivered once or twice daily via HFA-134a in mild to moderate persistent asthma in adult patients. Comparison with budesonide CFC. Respir. Med., 2003, 97, S20-8.
35. Escribano, A.; Tutuncu, A.; Lohr, I.; Carlholm, M.; Polanowski, T. Clinical comparability between the CFC and HFA budesonide pressurised metered-dose inhalers in paediatric patients with asthma: a randomised controlled trial. Curr. Med. Res. Opin., 2006, 22, 1085-92.
36. Newman, S.P.; Weisz, A.W.B.; Talaee, N.; Clarke, S.W. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax, 1991, 46, 712-6.
37. Newman, S.P. Spacer devices for metered dose inhalers. Clin. Pharmacokinet., 2004, 43, 349-60.
38. McFadden, E.R. Improper patient techniques with metered dose inhalers: clinical consequences and solutions to misuse. J. Allergy Clin. Immunol., 1995, 96, 278-83.
39. Bisgaard, H; Anhøj, J; wildhaber, J.H. In Drug Delivery to the Lung, Marcel Dekker Inc.: New York, 2002, pp. 389-420.
40. Global Initiative for Asthma (GINA). Instructions for inhaler and spacer use. http://www.ginasthma.com/OtherResourcesItem.asp?intId=30 (accessed June 9, 2008).
41. Lee, H.; Evans, H.E. Evaluation of inhalation aids of metered dose inhalers in asthmatic children. Chest, 1987, 91, 366-9.
42. Crimi, N.; Palermo, F.; Cacopardo, B.; Vancheri, C.; Oliveri, R.; Palermo, B.; Mistretta, A. Bronchodilator effect of Aerochamber and Inspirease in comparison with metered dose inhaler. Eur. J. Respir. Dis., 1987, 71, 153-7.
43. Newman, S.P. Newhouse, M.T. Effect of add-on devices for aerosol drug delivery: deposition studies and clinical aspects. J. Aerosol. Med., 1996, 9, 55-70.
44. Newman, S.P. Drug delivery to the lungs from dry powder inhalers. Curr. Opin. Pulmon. Med., 2003, 9, S17-20.
45. Borgström, L.; Bisgaard, H.; O'Callaghan C.; Pedersen S. In Drug Delivery to the Lung, Marcel Dekker Inc.: New York, 2002, pp. 421-48.
46. Atkins, P.J. Dry powder inhalers: an overview. Respir. Care, 2005, 50, 1304-12.
47. DeBoer, A.H.; Winter, H.M.I.; Lerk, C.F. Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers part 1. Inhalation characteristics, work of breathing and volunteers' preference in dependence of the inhaler resistance. Int. J. Pharm., 1996, 130, 231-44.
48. Meakin, B.J.; Ganderton, D.; Panza, I.; Ventura, P. The effect of flow rate on drug delivery from the Pulvinal, a high-resistance dry powder inhaler. J. Aerosol. Med., 1998, 11, 143-52.
49. Amirav, I.; Newhouse, M.T.; Mansour, Y. Measurement of peak inspiratory flow with in-check dial device to simulate lowresistance (Diskus) and high-resistance (Turbohaler) dry powder inhalers in children with asthma. Pediatr. Pulmonol., 2005, 39, 447-51.
50. Pearlman, D.S.; Kottakis, J.; Till, D.; Della Cioppa, G. Formoterol delivered via a dry powder inhaler (Aerolizer): results from long-term clinical trials in children. Curr. Med. Res. Opin., 2002, 18, 445-55.
51. Smith, I.J.; Parry-Billings, M. The inhalers of the future? A review of dry powder devices on the market today. Pulm. Pharmacol. Ther., 2003, 16, 79-95.
52. Becker, A.; Lemière, C.; Bérubé, D.; Boulet, L.-P.; Ducharme, F.M.; FitzGerald, M.; Kovesi, T.; on behalf of The Asthma Guidelines Working Group of the Canadian Network For Asthma Care. Summary of recommendations from the Canadian Asthma Consensus guidelines, 2003. C.M.A.J., 2005, 173, S3-11.
53. Selroos, O.; Borgström, L.; Ingelf, J. Performance of Turbuhaler® in patients with acute airway obstruction and COPD, and in children with asthma: understanding the clinical importance of adequate peak inspiratory flow, high lung deposition, and low in vivo dose variability. Treat. Respir. Med., 2006, 5, 305-15.
54. Agertoft, L.; Pedersen, S. Importance of training for correct Turbuhaler use in preschool children. Acta. Paediatr., 1998, 87, 842-7.
55. Schering Corporation. Asmanex® Twisthaler® Product Information. http://www.spfiles.com/piasmanex.pdf (accessed June 9, 2008).
56. Barry, P.W.; O'Callaghan, C. The influence of inhaler selection on efficacy of asthma therapies. Adv. Drug Deliv. Rev., 2003, 55, 879-923.
57. Newman, S.; Pitcairn, G.; Hirst, P.; Bacon, R.E.; O'Keefe, E.; Reiners, M.; Hermann, R. Scintigraphic comparison of budesonide deposition from two dry powder inhalers. Eur. Respir. J., 2000, 16, 178-83.
58. Pitcairn, G.R.; Lankinen, T.; Seppälä, O.-P.; Newman, S.P. Pulmonary drug delivery from the Taifun dry powder inhaler is relatively independent of the patient's inspiratory effort. J. Aerosol. Med., 2000, 13, 97-104.
59. Borgström, L.; Bondesson, E.; Morén, F.; Trofast, E.; Newman, S.P. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur. Respir. J., 1994, 7, 69-73.
60. Newman, S.; Malik, S., Hirst, P., Pitcairn, G.; Heide, A.; Pabst, J.; Dinkelaker, A.; Fleischer, W. Lung deposition of salbutamol in healthy human subjects from the MAGhaler dry powder inhaler. Respir. Med., 2002, 96, 1026-32.
61. Pitcairn, G.; Lunghetti, G.; Ventura, P.; Newman, S. A comparison of the lung deposition of salbutamol inhaled from a new dry powder inhaler, at two inhaled flow rates. Int. J. Pharm., 1994, 102, 11-8.
62. Newman, S.; Hollingworth, A.; Clark, A. Effect of different modes of inhalation on drug delivery from a dry powder inhaler. Int. J. Pharm., 1994, 102, 127-32.
63. Newman, S.P. How well do in vitro particle size measurements predict drug delivery in vivo? J. Aerosol. Med., 1998, 11, S97-104.
64. Dhand, R. New frontiers in aerosol delivery during mechanical ventilation. Respir. Care, 2004, 49, 666-77.
65. Geller, D.E. Choosing a nebulizer for cystic fibrosis applications. Curr. Opin. Pulm. Med., 1997, 3, 414-9.
66. Brocklebank, D.; Wright, J.; Cates, C.; on behalf of the National Health Technology Assessment Inhaler Review Group. Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering corticosteroids in asthma. BMJ, 2001, 323, 896-900.
67. 2 agonists bronchodilators in asthma. BMJ, 2001, 323, 901-5.
68. Ram, F.S.; Brocklebank, D.M.; White, J.; Wright, J.; Jones, P.W. Pressurised metered dose inhalers versus all other hand-held inhaler devices to deliver beta-2 agonist bronchodilators for non-acute asthma. Cochrane Database Syst. Rev., 2002, 1, CD002158.
69. Cates, C.J.; Bestall, J. Adams, N. Holding chambers versus nebulisers for inhaled steroids in chronic asthma. Cochrane Database Syst. Rev., 2006, 1, CD001491.
70. Weiss, K.B.; Paramore, C.; Liljas, B.; Revicki, D.A.; Luce, B.R. Patient satisfaction with budesonide Turbuhaler versus triamcinolone acetonide administered via pressurized metered-dose inhaler in a managed care setting. J. Asthma, 2005, 42, 769-76.
71. Welch, M.J.; Nelson, H.S.; Shapiro, G.; Bensch, G.W.; Sokol, W.N.; Smith, J.A.; Parasuraman, B.M. Comparison of patient preference and ease of teaching inhaler technique for Pulmicort Turbuhaler versus pressurized metered-dose inhalers. J. Aerosol. Med., 2004, 17, 129-39.
72. Sheth, K.; Bernstein, J.A.; Lincourt, W.R.; Merchant, K.K.; Edwards, L.D.; Crim, C.C.; Dorinsky, P.M. Patient perceptions of an inhaled asthma medication administered as an inhalation powder via the Diskus or as an inhalation aerosol via a metered-dose inhaler. Ann. Allergy Asthma Immunol., 2003, 91, 55-60.
73. van Schayck, C.P.; Bijl-Hofland, I.D.; Folgering, H.; Gerarda, S.; Cloosterman, M.; Akkermans, R.; Elshout, F.v.d.; van Weel, C. Influence of two different inhalation devices on therapy compliance in asthmatic patients. Scand. J. Prim. Health Care, 2002, 20, 126-8.
74. Liam, C.-K.; Lim, K.-H.; Wong, C. M.-M. Acceptance of the Accuhaler, a multi-dose powder inhaler, among asthmatic patients: a comparison with the pressurized metered-dose inhaler. Asian Pac. J. Allergy Immunol., 2000, 18, 135-40.
75. Engel, T.; Heinig, J.H.; Malling, H.J.; Scharling, B.; Nikander, K.; Madsen, F. Clinical comparison of inhaled budesonide delivered either via pressurized metered dose inhaler or Turbuhaler. Allergy, 1989, 44, 220-5.
76. Cotterell, E.M.; Gazarian, M.; Henry, R.L.; O'Meara, M.W.; Wales, S.R. Child and parent satisfaction with the use of spacer devices in acute asthma. J. Paediatr. Child. Health, 2002, 38, 604-7.
77. O'Reilly, J.F.; Weir, D.C.; Banham, S.; Basran, G.S.; Boyd, G.; Patel, K.R. Is high-dose fluticasone propionate via a metered-dose inhaler and Volumatic as efficacious as nebulized budesonide in adult asthmatics? Respir. Med., 1998, 92, 111-7.
78. Morice, A.H.; Hochmuth, L.; Ekelund, J.; Thorén, A.; Puterman, A.S. Comparable long-term safety and efficacy of a novel budesonide/formoterol pressurized metered-dose inhaler versus budesonide/formoterol Turbuhaler in adolescents and adults with asthma. Pulm. Pharmacol. Ther., 2008, 21, 32-9.
79. Morice, A.H.; Peterson, S.; Beckman, O.; Kukova, Z. Efficacy and safety of a new pressurised metered-dose inhaler formulation of budesonide/formoterol in children with asthma: a superiority and therapeutic equivalence study. Pulm. Pharamcol. Ther., 2008, 21, 152-9.
80. American Academy of Allergy, Asthma & Immunology. Pediatric Asthma: Promoting Best Practice. Guide for Managing Asthma in Children, American Academy of Allergy, Asthma & Immunology, Inc.: Milwaukee, WI, 2004.